Vitiligo, an autoimmune disorder characterised by skin depigmentation, is associated with reduced quality of life (QoL). Vitiligo may be under-reported, in part because misconceptions that it a cosmetic disease.This survey sought to characterise vitiligo prevalence and explore the relationship between sociodemographic clinical characteristics QoL population-based, multinational study.Participants aged ≥18 years were recruited via online panel Europe, Japan USA answer questions regarding...

Patients with vitiligo often have impaired quality of life (QOL) and experience substantial psychosocial burden.To explore the global association QOL mental health from patient perspective.This qualitative study cross-sectional population-based Vitiligo Life Impact Among International Communities (VALIANT) was conducted May 6, 2021, to June 21, 2021. Potential participants for this were recruited an online panel in 17 countries. Of 5859 surveyed adults (aged ≥18 years) who reported a...

BackgroundJanus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms.ObjectiveTo assess efficacy safety of povorcitinib (selective oral Janus inhibitor) in HS.MethodsThis placebo-controlled phase 2 study randomized patients with HS 1:1:1:1 to receive 15, 45, or 75 mg placebo for 16 weeks. Primary key secondary end points were mean change from baseline abscess inflammatory nodule count percentage achieving Clinical Response at week...

Recent cross-sectional studies suggest that restless legs syndrome (RLS) may be associated with an increased prevalence of cardiovascular disease (CVD) comorbidity or risk factors. We evaluated whether primary secondary RLS was incident in a retrospective cohort study within Kaiser Permanente Northern California (KPNC).We identified members KPNC and between 1999 2008 by algorithm incorporated longitudinal clinical records related to the diagnosis treatment comorbidities. then matched each...

Vitiligo is a chronic autoimmune disease affecting melanocytes, resulting in skin depigmentation. Patients with vitiligo often have reduced quality of life and comorbid conditions reported lack available treatments for their vitiligo.The Life Impact Among International Communities (VALIANT) study the first global survey to explore natural history management from perspectives patients healthcare professionals (HCPs).The recruited adults (≥ 18 years) diagnosed HCPs treating via an online panel...

Abstract Objective To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression. Background Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, has been approved for preventive treatment adults. CM depression are highly comorbid. Methods The 12‐week, Phase 3 HALO trial randomized quarterly (675 mg/placebo/placebo), monthly (675/225/225 mg), or placebo. Post hoc analyses evaluated...

First-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there no established second-line systemic therapy. Fibroblast growth factor receptor (FGFR)-2 fusions/rearrangements can be oncogenic drivers, occurring almost exclusively in intrahepatic cholangiocarcinoma, but little known about whether FGFR2 status affects the response to chemotherapy. We aimed evaluate effects of on survival outcomes patients receiving cholangiocarcinoma. In this...

Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) who had received first- or second-line systemic therapy for advanced/metastatic CCA before enrollment the phase II FIGHT-202 study (ClinicalTrials.gov identifier: NCT02924376).

Background Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion episodic (EM) is an important treatment goal. Objective To evaluate the effect of fremanezumab on rate from CM EM. Methods This phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group trial included a 28‐day pretreatment period 3‐month period. Patients received subcutaneous quarterly (675 mg at baseline) or monthly baseline;...

303 Background: Most patients (pts) with cholangiocarcinoma (CCA) are diagnosed advanced disease and ineligible for surgery. FGFR2 fusions/rearrangements oncogenic drivers present almost exclusively in pts intrahepatic CCA (iCCA; 10–16% of pts); however, little is known about the effects status on response to systemic chemotherapy. Memorial Sloan Kettering (MSK) obtains genomic sequencing data from all iCCA treated at institution. This provides a unique, rich database which profiling can be...

7528 Background: The engineered T-cell products axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) are FDA approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) mantle cell (MCL), respectively. This study investigated real-world rates of CRS ICANS following CAR-T. Methods: analyzed CIBMTR data US SUBJ receiving axi-cel or brexu-cel any indication from Oct 2020–Dec 2021 with ≥1 follow-up visit. were graded per American Society Transplantation Cellular...

Vitiligo is an autoimmune disease, causing skin depigmentation. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration their treatments. Here, we describe the of opinions on what constitutes meaningful change among participants two qualitative interview studies. Qualitative interviews were conducted a subgroup adolescent adult from pivotal phase 3 clinical trials ruxolitinib cream (Study 1) real-world panel 2). Participants asked about disease burden,...

276 Background: CCA is associated with poor prognosis and reduced QoL. In the phase 2 FIGHT-202 study (NCT02924376) of selective oral FGFR1–3 inhibitor pemigatinib, 35.5% 46.7% pts previously treated advanced FGFR2 fusions/rearrangements (RE) had a complete or partial response (CR/PR) stable disease (SD), respectively; 14.9% progressive (PD) [Abou-Alfa et al., Lancet Oncology 2020;21:671-684]. QoL was an exploratory endpoint. Methods: Pts received pemigatinib 13.5 mg once daily (21-day...

To assess the effect of fremanezumab versus placebo on medication overuse and acute headache use in patients with chronic migraine (CM).

As determinants of the opioid epidemic are several, describing patterns prescription over time is importance.To characterize prescribing opioids per US region and physician specialty from 2012 to 2015.Truven Health Analytics MarketScan® Databases were used obtain data on rates for years 2012-2015. Opioids included in study tramadol, hydrocodone, codeine, oxycodone, oxymorphone, methadone, fentanyl.Starting sample consisted 5,860,096 individuals. An increase prescriptions was seen codeine...

e19008 Background: CLL/SLL is a treatable malignancy, which responsive to therapies that include bendamustine. However, as with many alkylating agents, there concern for the development of secondary malignancies and MDS after exposure We evaluated risk using electronic medical records from geographically diverse cohort cancer patients (pts). Methods: Pathologically confirmedCLL/SLL pts any bendamustine were identified in Flatiron Health database (FHD, Health, New York [122016]). This...

This study evaluated the effects of concomitant pravastatin and paroxetine use on incidence Type 2 Diabetes Mellitus (T2DM).A new-user retrospective cohort design was employed using data selected from US health insurance claims databases (OptumInsight MarketScan) between July 1, 2002, December 31, 2009. Patients included were age ≥18; newly prescribed or paroxetine; enrolled in database for ≥180 days prior to index date (i.e., first prescription incident drug). assigned either user groups....

Background: Autoimmune hemolytic anemia (AIHA) is a rare acquired disorder characterized by autoantibodies targeted against erythrocyte membrane antigens, leading to accelerated red blood cell destruction. The estimated incidence of AIHA 1.3–2.9 per 100,000/year in North America and Western Europe, which warm (wAIHA) accounts for 60%–70% cases. In wAIHA, autoimmunity typically immunoglobulin G mediated with thermal reactivity range (~37°C). Approximately 50% wAIHA cases are as primary...

This study reports psychometric testing of the facial and total Vitiligo Area Scoring Index quantitative clinical instruments (F-VASI [range: 0–3], T-VASI 0–100], respectively) using data from two phase 3 randomized, vehicle-controlled studies ruxolitinib cream (TRuE-V1/TRuE-V2), largest vitiligo trials conducted to date. Because VASI assessment is required by regulatory authorities, we evaluated properties confirmed thresholds for clinically meaningful change. The TRuE-V1/TRuE-V2 full...

Aim: To understand cholangiocarcinoma symptoms, diagnosis and treatment experience from the patient caregiver perspective, including cholangiocarcinoma's impact on daily life, quality of life (QoL) mental health. Methods: Patients caregivers participated in two online surveys (in partnership with Cholangiocarcinoma Foundation). Results: The survey data (n = 707) show a substantial QoL health, 34% patients reporting symptoms consistent moderately severe/severe depression. 60) that although...

277 Background: Patients (pts) with CCA typically present advanced disease and face a poor prognosis impaired quality of life (QoL). Despite improvements in therapies, the impact on pts’ daily lives has been rarely studied. This pt-focused survey explored diagnostic journey, including work status, QoL psychosocial impacts CCA. Methods: Pts were recruited partnership Cholangiocarcinoma Foundation from Aug 23 through Sept 20, 2019, categorized by AJCC stage. participated 30-min online to...